Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
Celcuity shares declined by 12.6% despite the company receiving its first FDA approval for a breast cancer treatment.
- Intelligence Anchor: Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
- Core Takeaway: Celcuity shares declined by 12.6% despite the company receiving its first FDA approval for a breast cancer treatment.
- Signal Velocity: 6 score across 8 independent media sources and 9 indexed articles.
- Forecast Model: Story predicted to decelerate within 24h.
Who reported it (9)
- Managing Gedatolisib IV Delivery and Toxicity Profiles in Breast Cancer CancerNetwork · 99d ago
- Celcuity (CELC) Sees a 12.6% Decline in Stock Price GuruFocus · 99d ago
- FDA Approves Revtorpyk to Help Treat Certain Form Advanced Breast Cancer WebMD · 99d ago
- Celcuity shares fall as launch delay eclipses US approval for breast cancer drug Reuters · 99d ago
- Celcuity’s breast cancer drug approved, its first STAT · 99d ago
- FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer OncLive · 99d ago
- With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma Fierce Pharma · 99d ago
- US FDA approves Celcuity's breast cancer drug Reuters · 99d ago
- Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits Investor's Business Daily · 99d ago
Where it stands
The FDA has granted approval for Revtorpyk, also identified as Gedatolisib, for the treatment of hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. This marks the first FDA approval for Celcuity, the company developing the drug.
Coverage from outlets including Reuters, STAT, and Investor's Business Daily highlights that the stock experienced a double-digit decline following the announcement. Reporting suggests that investor focus shifted toward a reported launch delay for the medication, which overshadowed the regulatory approval news.
Industry analysis from Fierce Pharma indicates potential future interest from larger pharmaceutical firms. Observers will monitor how Celcuity manages the implementation of the drug’s delivery and toxicity profiles, as well as the eventual timing of the commercial launch.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 96d ago.
Answered
What drug did Celcuity receive approval for?
The FDA approved Revtorpyk, also referred to as Gedatolisib, for use in specific breast cancer cases.
Why did Celcuity stock price fall?
According to Reuters, a launch delay for the new drug has eclipsed the positive news of FDA approval, resulting in a 12.6% decline in share price.
What is the intended use of the drug?
It is approved for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, used in combination with fulvestrant and potentially palbociclib.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Will this trend continue gaining momentum or fade within 24 hours?
Cast your anonymous vote to register reader sentiment on news cycle velocity.
Topics
From around our network
- SpaceX Share for Every Kid Needs a Charity and Treasury's Approval daybreakwire.com
Related trends
CEOs Pushed White House to Delay Ultra-Processed Food Policy
Corporate lobbying and White House maneuvering have collided over the FDA's controversial new ultra-processed food definition.
Breast cancer checks missing most women under 50 who are at risk, says study
Current GP referral rules for young women miss 95% of those who develop breast cancer within a decade, a major study reveals.
FDA Announces Recall on Berries Sold in 8 States for Potential E. Coli Contamination
The FDA and Publix have issued a recall for frozen berries across eight states following an E. coli outbreak linked to the products.
More cases reported in cyclospora outbreak not linked to lettuce: FDA data
Cyclospora infections are rising across the U.S., with recent data indicating new outbreak clusters that fall outside the traditional link to lettuce products.
Can you eat lettuce safely during the cyclospora outbreak? Advice from an infectious disease expert
Cyclospora outbreaks are fueling regional health concerns and economic strain in the restaurant industry as officials navigate complex data and public messaging.
Toward a test of medical AI superintelligence
A new medical AI framework sparks debate over FDA benchmarks and the path to superintelligence.